Literature DB >> 20600476

Genetic control of immune responses to influenza A matrix 2 protein (M2).

Julia A Misplon1, Chia-Yun Lo, Jon D Gabbard, S Mark Tompkins, Suzanne L Epstein.   

Abstract

Vaccines should protect genetically diverse populations. Therefore we tested the candidate "universal" influenza A matrix protein 2 (M2) vaccine in multiple mouse strains. Mice were primed with M2 DNA and boosted with M2 recombinant adenovirus (rAd). C57BL/6 (B6) mice developed no antibody or T-cell response to M2, while BALB/c responded strongly. CBA responses were intermediate. Both MHC and background genes influenced responsiveness. To improve low responses we immunized with adjuvanted peptide-carrier conjugates, or co-immunized with nucleoprotein (NP), which can augment T-cell help. The conjugate vaccine enhanced some outcomes but not others. Co-immunizing with NP improved outcomes over either NP or M2 immunizations alone. These results have implications for vaccination of genetically diverse populations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600476     DOI: 10.1016/j.vaccine.2010.06.069

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.

Authors:  D G Eliasson; A Omokanye; K Schön; U A Wenzel; V Bernasconi; M Bemark; A Kolpe; K El Bakkouri; T Ysenbaert; L Deng; W Fiers; X Saelens; N Lycke
Journal:  Mucosal Immunol       Date:  2017-03-01       Impact factor: 7.313

2.  Safe Recombinant Outer Membrane Vesicles that Display M2e Elicit Heterologous Influenza Protection.

Authors:  Hannah C Watkins; C Garrett Rappazzo; Jaclyn S Higgins; Xiangjie Sun; Nicole Brock; Annie Chau; Aditya Misra; Joseph P B Cannizzo; Michael R King; Taronna R Maines; Cynthia A Leifer; Gary R Whittaker; Matthew P DeLisa; David Putnam
Journal:  Mol Ther       Date:  2017-02-16       Impact factor: 11.454

3.  Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules.

Authors:  A B Rodriguez-Peña; J Gomez-Rodriguez; R L Kortum; D C Palmer; Z Yu; G C Guittard; E A Wohlfert; P B Silver; J A Misplon; C L Sommers; L Feigenbaum; S L Epstein; R R Caspi; Y Belkaid; N P Restifo; L E Samelson; L Balagopalan
Journal:  Gene Ther       Date:  2015-06-18       Impact factor: 5.250

4.  Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice.

Authors:  Noopur Bhatnagar; Ki-Hye Kim; Jeeva Subbiah; Bo Ryoung Park; Eun-Ju Ko; Baik-Lin Seong; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2021-12-18       Impact factor: 5.970

5.  Adjuvant effects of killed Lactobacillus casei DK128 on enhancing T helper type 1 immune responses and the efficacy of influenza vaccination in normal and CD4-deficient mice.

Authors:  Yu-Jin Jung; Ki-Hye Kim; Eun-Ju Ko; Youri Lee; Min-Chul Kim; Young-Tae Lee; Cheol-Hyun Kim; Subbiah Jeeva; Bo Ryoung Park; Sang-Moo Kang
Journal:  Vaccine       Date:  2020-07-13       Impact factor: 3.641

6.  Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model.

Authors:  Graeme E Price; Chia-Yun Lo; Julia A Misplon; Suzanne L Epstein
Journal:  J Virol       Date:  2014-03-12       Impact factor: 5.103

7.  Influenza virus-like particles containing M2 induce broadly cross protective immunity.

Authors:  Jae-Min Song; Bao-Zhong Wang; Kyoung-Mi Park; Nico Van Rooijen; Fu-Shi Quan; Min-Chul Kim; Hyun-Tak Jin; Andrew Pekosz; Richard W Compans; Sang-Moo Kang
Journal:  PLoS One       Date:  2011-01-18       Impact factor: 3.240

8.  Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza A virus in mice.

Authors:  Eun-Ha Kim; Jun-Han Lee; Philippe Noriel Q Pascua; Min-Suk Song; Yun-Hee Baek; Hyeok-Il Kwon; Su-Jin Park; Gyo-Jin Lim; Arun Decano; Mohammed Ye Chowdhury; Su-Kyung Seo; Man Ki Song; Chul-Joong Kim; Young-Ki Choi
Journal:  Virol J       Date:  2013-04-03       Impact factor: 4.099

9.  Comparison of the effectiveness of antibody and cell-mediated immunity against inhaled and instilled influenza virus challenge.

Authors:  Katie Rivers; Larry E Bowen; Jin Gao; Kevin Yang; John E Trombley; J Kyle Bohannon; Maryna C Eichelberger
Journal:  Virol J       Date:  2013-06-19       Impact factor: 4.099

10.  Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design.

Authors:  Denise A Kaminski; F Eun-Hyung Lee
Journal:  Front Immunol       Date:  2011-12-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.